Skip to main content

Table 3 Response to treatment at 1 year

From: Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series

  Overall (n = 15) Initial therapy (n = 7) Second-line therapy (n = 8)
Variable Baseline 1-Year P value Baseline 1-Year P value Baseline 1-Year P value
UPCR (g/g) 8.2 (6.6–11.1) 0.3 (0.2–0.7) <0.001 6.9 (5.2–10.2) 0.2 (0.1–0.5) 0.02 10.1 (8–11.7) 0.6 (0.3–0.7) 0.01
Creatinine (mg/dL) 1.2 (0.8–1.5) 1.0 (0.8–1.2) 0.44 0.8 (0.5–0.9) 0.8 (0.7–1.0) 0.13 1.3 (1.2–2.1) 1.2 (1.1–1.7) 0.02
Albumin (mg/dL) 2.7 (2.5–2.8) 4.2 (4–4.4) <0.001 2.7 (2.5–2.8) 4.2 (3.9–4.4) 0.02 2.6 (2.4–3.1) 4.2 (4.0–4.4) 0.01
Cholesterol (mg/dL)a 350 (252–371) 189 (148–220) 0.001 341 (252–367) 167 (128–191) 0.02 371 (249–438) 207 (155–251) 0.02
Triglycerides (mg/dL) 172 (122–270) 189 (148–220) 0.40 134 (77–192) 105 (80–244) 0.74 177 (155–546) 182 (152–204) 0.24
IgG (mg/dL)b 314 (199–551) 730 (538–908) 0.003 499 (296–731) 806 (676–1027) 0.02 199 (198–308) 611 (364–676) 0.08
  1. Data are presented as median (interquartile range). Baseline and 1 year values compared with Wilcoxon signed-rank test
  2. a1 patient in the second-line therapy group did not have baseline cholesterol or triglycerides
  3. bthree patients in the second-line therapy group had missing baseline IgG
  4. Abbreviations: IgG immunoglobulin G, UPCR urinary protein:creatinine ratio